Nicholas Thomas Carter

Elanco Tiergesundheit AG manufactures animal vaccines. The firm provides pet health, livestock and Bioprotection products. The company's products include Atopica, Capstar, Deramaxx, Fortekor, Interceptor, Milbemax, Parc-tic and Sentinel. It is headquartered in Basel, Switzerland.

Lonza Biologics Plc manufactures monoclonal antibodies, recombinant proteins and diagnostic monoclonal antibodies. The company was founded in 1897 and is headquartered in Slough, the United Kingdom.

Part of Novartis AG, Novartis Pharmaceuticals is a German company that manufactures pharmaceutical products. The company is based in Basel, Germany.

Lonza Swiss Finanz AG engages in the provision of financing services within the companies of Lonza Group AG. It also invests in domestic and foreign industrial and commercial firms. The company was founded on December 23, 1974 and is headquartered in Basel, Switzerland.

Lonza AG engages in the research in as well as development, production, and distribution of chemical products and materials. The firm also carries out investment and lending transactions. The company was founded on December 7, 1897 and is headquartered in Visp, Switzerland.

Evolva SA is a Swiss-headquartered, international pharmaceutical biotech company focused on the discovery and development of drugs based on its distinctive and proprietary genetic chemistry platform. The company was founded in Switzerland in 2004 based on US/Danish technology. Evolva is headquartered in Allschwil/Basel with operations in Denmark, India and the USA. The Company has raised CHF 38.2 million of equity to date and employs 75 persons of whom 30 are based in Allschwil. The firm's strategy and business approach is based on five pillars that offer a sustainable development path for creating a successful company, which include Building a balanced portfolio. Evolva focuses on orally available small molecules in the belief that they are more convenient for patients and more cost-effective both from manufacture and administration points of view for the society, focus on differentiated pharmaceutical products with major benefits. Focusing on cardiovascular/renal and infectious diseases. Together they cause more than 50% of all deaths worldwide. Most of the top 20 pharmaceutical companies are active in both sectors, and all are active in one of the two sectors - hence widening Evolva's opportunities to partner. Building technology platform as the source of this differentiation. Evolva finds different structures with different properties from those found by the 99% of the industry that focuses on synthetic chemistry or proteins. Openness to unusual markets. The biotech business model has changed. As well as the established markets new opportunities arise in emerging countries such as India and China, and in adjacent sectors such as treatments against potential bio-terrorist and bio-warfare agents and the production of pharmaceutical and industrial chemical intermediates. Cost-effective implementation. Evolva places different functions around the globe according to where local conditions best suit. This approach both reduces Evolva's cost base and increases access to revenues, partners and talent. Evolva sees revenues and partners as important because they provide additional flexibility, resources and talent. Also, they provide important opportunities to better understand, and better meet, the needs of current and future customers.

Diacon Technologies, Inc. supplies mold inhibition products to sawmill industry for the control of mold on lumber and wood composites. The company was founded on March 31, 2011 and is headquartered in Bellingham, WA.